Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMoath AlbliwiANAhmed NabilEAElizabeth M. Azzato

Discussion

Loading...

Member takes

Overview

Retrospective study links TP53 and PPM1D mutations to decreased survival in AML, suggesting clinically significant prognostic implications.

Key Points

  • This research investigates the prognostic importance of TP53 and PPM1D mutations in acute myeloid leukemia.
  • Single-center retrospective study of AML patients from 2015 to 2023
  • Assessment of treatment response, overall survival, and event-free survival
  • Mutations detected using next-generation sequencing
  • Cytogenetic abnormalities identified by karyotyping
  • Survival estimated by Kaplan–Meier and compared by log-rank test.
  • TP53 mutations found in 19% of patients, associated with lower odds of complete response
  • Median overall survival for TP53 mutations was 5.6 months vs 15 months for wildtype
  • PPM1D mutations less common at 2.6%, linked to worse overall survival
  • Presence of TP53 mutations correlated with higher mortality and shorter event-free survival.

Cite This Study

Albliwi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d669https://doi.org/10.1182/blood-2025-5168
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.2025 · 1 citations
  2. 2Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation2025
  3. 3Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  4. 4Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  5. 5Prognosis of Acute Myeloid Leukemia Based on TP53 Mutation Among Adult Patients: A Systematic Review and Meta-Analysis.2026